Abcam, ab192264, Anti-Interferon alpha 6 antibody [EPR16355]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal Interferon alpha 6 antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR16355,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Interferon alpha 6 also known as IFN-α6 is part of the Type I interferons. This protein is found in humans and has an approximate mass of 19.5 kDa. It belongs to the larger interferon family which includes various alpha beta and omega subtypes. IFN-α6 is mainly expressed in leukocytes including B cells T cells and dendritic cells. In terms of structure IFN-α6 is a member of the cytokine receptor family sharing similarities with other members like IFN-α2 but differing slightly in sequences.
Biological function summary
Interferon alpha 6 contributes to the body's immune responses against viral infections and tumors. It attracts immune cells to infected sites and enhances the antigen presentation process. It interacts with the interferon alpha/beta receptor (IFNAR) initiating a signaling cascade that involves JAK-STAT pathways. This activation leads to the expression of antiviral proteins and boosts the immune system's ability to clear pathogens. IFN-α6 forms part of the larger interferon complex working in coordination with other IFN-α subfamily members to amplify immune responses.
Pathways
Interferon alpha 6 plays an important role in both the JAK-STAT signaling pathway and the antiviral immune response pathway. JAK-STAT involves kinase proteins such as JAK1 and TYK2 which become activated upon IFN-α6 binding to its receptor. This activation enables the transcription of interferon-stimulated genes (ISGs) that inhibit viral replication. Similarly in the immune response pathway it enhances the expression of major histocompatibility complex (MHC) molecules aiding in the identification of infected cells by T cells. IFN-α6 shares these pathways with other interferons like IFN-α2 and IFN-β which also influence similar immune processes.
Interferon alpha 6 has been linked to interferonopathies and certain types of cancers like melanoma. Dysregulation of IFN-α6 can contribute to exaggerated inflammatory responses leading to conditions such as systemic lupus erythematosus (SLE). In these disorders an abnormal increase in interferons can cause chronic inflammation. Additionally in cancers it may hinder the evasion mechanisms of tumor cells promoting tumor suppression. Through its interaction with proteins in these diseases including IFNAR JAK1 and TYK2 IFN-α6 remains an important focus for research in therapeutic interventions.